Skip to main content
Shilpa Medicare Ltd. logo

Shilpa Medicare Ltd. — Investor Relations & Filings

Ticker · SHILPAMED ISIN · INE790G01031 LEI · 3358002PKUL8S2RNJO60 BSE.NS Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2026-01-30 Board/Management Inform…
Country IN India
Listing BSE.NS SHILPAMED

About Shilpa Medicare Ltd.

https://vbshilpa.com/

Shilpa Medicare Ltd. is a research-led organization specializing in the development, manufacture, and commercialization of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company maintains a significant focus on the oncology segment, producing a wide range of high-potency anti-cancer drugs. Its capabilities extend to diverse therapeutic areas, including ophthalmology, dermatology, and biosimilars. Shilpa Medicare operates manufacturing facilities compliant with international regulatory standards such as the USFDA and EU-GMP. The organization emphasizes complex chemistry and advanced drug delivery systems, offering a portfolio that includes oral solids, injectables, and transdermal patches. Through its R&D infrastructure, the company provides contract research and manufacturing services to global partners, supporting the lifecycle of generic and innovative pharmaceutical products.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a letter dated 30 January 2026 from Shilpa Medicare Limited addressed to stock exchanges, informing them about a scheduled Board Meeting on 6 February 2026 to consider and approve unaudited financial results for the quarter and nine months ended 31 December 2025. It references Regulation 29 of SEBI (LODR) Regulations, 2015, which pertains to disclosure of events or information by listed entities. The document is an intimation or announcement about an upcoming board meeting and financial results approval, not the financial results report itself. The document length is short (1930 characters) and it does not contain any financial data or analysis. Therefore, it is an announcement of a board meeting and financial results approval, which fits best under Board/Management Information (MANG).
2026-01-30 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated January 28, 2026, from Shilpa Medicare Limited announcing that their subsidiary, Shilpa Biologicals Pvt Ltd, along with mAbTree Biologics AG, has received Orphan Drug Designation from the U.S. FDA for a biologic product targeting rare blood cancers. The text includes regulatory references (SEBI Listing Regulations), but it is clearly a public announcement of a regulatory milestone and not a financial report, earnings release, or detailed management discussion. It does not contain financial data, audit information, or meeting materials. The document is a regulatory announcement about a significant corporate development related to drug designation and regulatory progress. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-01-28 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the assignment of an ESG rating by an external ESG rating provider. It explicitly states that the rating was assigned based on publicly available data and was not commissioned by the company. The document references SEBI regulations related to disclosure requirements. The content is an announcement of an ESG rating assignment rather than a detailed ESG report or full environmental/social disclosure. The document length is short (1843 characters), and it serves as a regulatory disclosure under SEBI rules. Therefore, it fits best under Environmental & Social Information (SR) as it relates to ESG rating disclosure, but since it is a brief announcement rather than a full ESG report, and given the regulatory context, it is more appropriate to classify it as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. Hence, the classification is Regulatory Filings (RNS).
2026-01-16 English
General Updates
Capital/Financing Update Classification · 95% confidence The document is an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the sale of a wholly owned subsidiary. It provides details about the transaction, including the date, consideration, and buyer information. The document is addressed to stock exchanges and serves as a regulatory announcement of a corporate event (disposal of subsidiary shares). It does not contain financial statements or detailed financial analysis but is a formal notification of a capital structure change. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 4706 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is CAP with high confidence.
2026-01-15 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges and regulatory bodies regarding compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. It includes certificates from the Registrar and Share Transfer Agent certifying the details of securities dematerialized/rematerialized for the quarter ended 31st December 2025. The document is short (3576 characters) and primarily serves as a compliance certificate submission rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or audit information. It is a regulatory compliance submission related to share transfer and depository regulations. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document.
2026-01-06 English
General Updates
Regulatory Filings Classification · 100% confidence The document is a formal communication addressed to stock exchanges regarding an ex-parte ad-interim injunction order received from the High Court of Delhi. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events by listed companies. The content details a legal injunction related to patent infringement, the company's response, and the impact on operations and finances. There are no financial statements or detailed financial analysis present, and the document serves as a regulatory disclosure of a legal event affecting the company. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-12-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.